<img alt="" src="https://secure.perk0mean.com/184504.png" style="display:none;">

Newsroom

Media Coverage

September 13, 2021 
Drug Discovery Trends

Neta Bendelac, Senior Director, Strategy, speaks with Drug Discovery Trends about COVID testing, and how clinical trials need to stay ahead of new mutations.

neta-bendelacThe rapid pace of development of COVID-19 vaccines and antibodies has redefined expectations for clinical trials. As SARS-CoV-2 variants such as Delta continue to fuel the epidemic, the industry must continue to ensure testing and clinical trials stay ahead of mutations.

To get a clearer sense of what the ramifications of this accelerated development will be for the industry at large, we spoke with Neta Bendelac, Sr. Director, Strategy at 4G Clinical.


Drug Discovery & Development: What impact has the pandemic had on trials for COVID-19 therapies?

Neta Bendelac: Speed was the most important factor for the early COVID-19 studies as many sponsors raced to get promising therapies and potential vaccines into the clinic. We all felt the urgency, all day, every day. It made sense for the FDA to stick to the gold standard of placebo trials so that the results would be clear.

Unfortunately, many of the therapies didn’t have matching placebos, so the studies needed to have both blinded and unblinded staff at the clinical sites. This added an element of complexity to maintaining the blind and protecting the integrity of the data.

View the complete article at Drug Discovery Trends.

MEDIA CONTACT

AMY RIPSTON

370 Washington Street

Wellesley, MA 02481

781.694.1343

amy@4gclinical.com